- Home
Clinical trials

Search for a clinical trial
Filter
Filter
Geographical location
Type of cancer
Refine your search
Age
Phase
Search for a clinical trial
192 result(s)
- ENT/Head and Neck CancersParis219885 GALAXIES H&N-202A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
CHRISTOPHE LE TOURNEAU
- Colorectal cancerSaint-CloudADAGE - Prodige 34Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.
- SarcomasParisADCT-601-102A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.
SARAH WATSON
- Saint-CloudAIPACAIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel
ETIENNE BRAIN
- Lung cancerParisAK112-301-HARMONiA randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.
NICOLAS GIRARD
- Breast cancerParis, Saint-CloudALCINA-2Analysis of Circulating Tumor Markers in Blood
FRANCOIS-CLEMENT BIDARD
- Breast cancerParis, Saint-CloudALCINA-4 (IC 2020-11)Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4
LUC CABEL, FRANCOIS-CLEMENT BIDARD
- Paris, Saint-CloudALCYTA (IC 2020-12)Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA
NICOLAS GIRARD
- Saint-CloudALPHABETRandomized phase III trial of the administration of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with a PIK3CA mutation and previously treated for advanced HER2+ cancer
FRANCOIS-CLEMENT BIDARD
- Saint-CloudAMEBICA - Prodige 38Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours.
- Saint-CloudAML LI-1A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME
JACQUES VARGAFTIG
- Saint-CloudAPACaPMulticenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
- Saint-CloudAcSé PembrolizumabSecured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types.
CAROLE SOUSSAIN
- Saint-CloudAcSé VemurafenibSecured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
ETIENNE BRAIN
- SarcomasParisBFR ESS 01Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS
SOPHIE PIPERNO-NEUMANN
- ParisBGB-A317-A3055-101A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors.
CHRISTOPHE LE TOURNEAU
- Lung cancerParisBGB-LC-201A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.
NICOLAS GIRARD
- Lung cancerParisBI 1479-0008 (BEAMION LUNG 2)Beamion LUNG-2: A Phase III, open-label, randomized, activecontrolled,;multi-centre trial evaluating orally administered;BI 1810631 compared with standard of care as first-line treatment;in patients with unresectable, locally advanced or metastatic nonsquamous;non-small cell lung cancer harbouring HER2 tyrosine;kinase domain mutations.
NICOLAS GIRARD
- Lung cancerParisBI1438-0009 (DAREON 9)DAREONTM-9: A Phase Ib open-label dose escalation and dose;confirmation safety study of intravenous BI 764532 in;combination with topotecan for the treatment of patients with;small cell lung cancer
PAULINE DU RUSQUEC
- Bladder cancerParisBLAD-RAD01 (GETUG-AFU V07)Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial.
GILLES CREHANGE
- Saint-CloudBLOCAGE 01Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line
CAROLE SOUSSAIN
- ParisBNT113-01A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)
CHRISTOPHE LE TOURNEAU
- Saint-CloudBO25430AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD·SPONSORED TRASTUZUMAB EMTANSINE STUDY.
FLORENCE LEREBOURS
- Breast cancerParisBRAINSTORMA Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program
EDITH BORCOMAN
- Lung cancerParisBRIDGE (D9106C00002)A multicentre, Phase II, single-arm, interventional study of;neoadjuvant durvalumab and platinum-based chemotherapy;(CT), followed by either surgery and adjuvant durvalumab or;chemoradiotherapy (CRT) and consolidation durvalumab, in;participants with resectable or borderline resectable stage;IIB-IIIB Non-small Cell Lung Cancer (NSCLC)
NICOLAS GIRARD
- Saint-CloudBYLieve (CBYL719X402)A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment
FLORENCE LEREBOURS
- LeukemiaSaint-CloudBackbone Inter-Group-1 (BIG-1)Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial
JACQUES VARGAFTIG
- LymphomaSaint-CloudCA-4948-101An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphom.
CAROLE SOUSSAIN
- Saint-CloudCANTO (Saint-Cloud)A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer
FLORENCE LEREBOURS
- Childhood and adolescent cancersParisCDRB436G2401An open label, multi-center roll-over study to assess longterm;effect in pediatric patients treated with Tafinlar;(dabrafenib) and/or Mekinist (trametinib)
ISABELLE AERTS GAJDOS